Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cell Reports. Medicine|August 2, 2021
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumorsAna Portelinha, Scott Thompson, Roger A Smith, et al.Bioorganic & Medicinal Chemistry Letters|April 20, 2002
Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesisRoger A Smith, Donald L Hertzog, Martin H Osterhout, et al.Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonistsGaetan H Ladouceur, James H Cook, Donald L Hertzog, et al.Bioorganic & Medicinal Chemistry Letters|November 17, 2006
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivativesRoger A Smith, Zahra Fathi, Su-Ellen Brown, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2007
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesityRoger A Smith, Zahra Fathi, Furahi Achebe, et al.Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituentUday R Khire, Donald Bankston, James Barbosa, et al.Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitorJacques Dumas, Holia Hatoum-Mokdad, Robert N Sibley, et al.Pageof 2